Skip to main content

Advertisement

Table 1 Population characteristics and comparison of patients with versus without sustained remission

From: Window of opportunity to achieve major outcomes in early rheumatoid arthritis patients: how persistence with therapy matters

  Whole population (N = 107) Patients with SR (n = 68) Patients without SR (n = 39) p Valuea
Sociodemographic variables     
 Female sex, n (%) 95 (88.8) 56 (82.4) 39 (100) 0.004
 Age at baseline, years, (mean ± SD) 39.1 ± 13.3 38.6 ± 13.7 39.1 ± 13.4 0.85
 Years of formal education, (mean ± SD) 11.1 ± 3.9 13.4 ± 4.1 8.6 ± 3 0.04
 Current smokers, n (%) of patients 9 (8.4) 7 (10.3) 2 (22.2) 0.48
Disease characteristics at baselineb     
 Disease duration, months 5 (3.4–7) 4.2 (2.9–4.9) 4.9 (2.6–6.2) 0.22
 Patients with RF, n (%) 88 (82.2) 54 (79.4) 34 (87.2) 0.43
 Patients with ACCP, n (%) 92 (86) 57 (83.8) 35 (89.7) 0.57
 DAS28 6 (5.1–7.1) 5.7 (4.6–6.7) 7 (6.1–7.8) 0.001
 HAQ 1.5 (0.9–2.1) 1.3 (0.6–2) 1.9 (1.5–2.4) 0.000
 Patients with erosions, n (%) 11 (10.3) 8 (11.8) 3 (7.7) 0.74
Number (%) of patients with ≥1 comorbidity 89 (77.4) 57 (83.8) 28 (71.8) 0.15
Number of comorbidities/patient 1 (1–2) 1 (1–2) 2 (1–2.8) 0.08
Cumulative treatment characteristicsb     
 Patients with corticosteroids, n (%) 58 (54.2) 33 (48.5) 25 (64.1) 0.16
 Number of DMARDs/patient 2.2 (1.9–2.9) 2.2 (1.7–2.8) 2.6 (2–3) 0.03
 Number (%) of patients with ≥1 non-persistence period 74 (69.2) 46 (67.6) 28 (71.8) 0.83
 Follow-up at first non-persistence period,c mo 13 (1–31) 19 (7–31) 7 (1–23.5) 0.02
 Persistence duration, mod 42 (30–48) 42 (30–48) 36(18–48) 0.07
  1. ACCP Anti-cyclic citrullinated peptide antibodies, DAS28 Disease Activity Score in 28 joints, DMARD Disease-modifying anti-rheumatic drug, HAQ Health Assessment Questionnaire, RF Rheumatoid factor, SD Standard deviation, SR Sustained remission
  2. a p < 0.05 is statistically significant
  3. bData are presented as median (25th–75th interquartile range) unless otherwise indicated
  4. cRestricted to 74 patients with ≥1 non-persistence period
  5. dIn the whole population